Sentiment for Progenics Pharmaceuticals Inc (NASDAQ:PGNX)
Progenics Pharmaceuticals Inc (NASDAQ:PGNX) institutional sentiment decreased to 1.18 in Q2 2019. Its down -0.60, from 1.78 in 2019Q1. The ratio worsened, as 60 investment professionals opened new or increased equity positions, while 51 decreased and sold their holdings in Progenics Pharmaceuticals Inc. The investment professionals in our partner’s database now own: 62.67 million shares, down from 63.56 million shares in 2019Q1. Also, the number of investment professionals holding Progenics Pharmaceuticals Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 13 Reduced: 38 Increased: 42 New Position: 18.
Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company has market cap of $432.97 million. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen -targeted positron emission topography (PET) imaging agent for prostate cancer. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products.
The stock increased 0.20% or $0.01 during the last trading session, reaching $5.01. About 581,048 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has declined 35.26% since December 4, 2018 and is downtrending. It has underperformed by 35.26% the S&P500.
Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on March, 12. They expect $-0.16 earnings per share, up 5.88 % or $0.01 from last year’s $-0.17 per share. After $-0.22 actual earnings per share reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -27.27 % EPS growth.
Rice Hall James & Associates Llc holds 0.46% of its portfolio in Progenics Pharmaceuticals, Inc. for 2.24 million shares. Farallon Capital Management Llc owns 5.54 million shares or 0.28% of their US portfolio. Moreover, Highland Capital Management Lp has 0.26% invested in the company for 716,880 shares. The New York-based Pinnacle Associates Ltd has invested 0.19% in the stock. Point72 Asset Management L.P., a Connecticut-based fund reported 5.86 million shares.
Since January 1, 0001, it had 4 insider buys, and 0 sales for $3.86 million activity.
More notable recent Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) news were published by: Seekingalpha.com which released: “Progenics Q2 top-line up 156% – Seeking Alpha” on August 09, 2019, also Fool.com with their article: “Progenics Pharmaceuticals (PGNX) Q1 2019 Earnings Call Transcript – Motley Fool” published on May 10, 2019, Globenewswire.com published: “Progenics Pharmaceuticals Comments on Velan Capital’s Preliminary Proxy Statement – GlobeNewswire” on May 07, 2019. More interesting news about Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) were released by: Seekingalpha.com and their article: “Progenics: Volatility Shaking The Tree After A Rough Q2 Earnings – Seeking Alpha” published on August 26, 2019 as well as Globenewswire.com‘s news article titled: “INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders â€“ AMTD, TIF, MDCO, PGNX – GlobeNewswire” with publication date: December 04, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.